ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 731

C3 Activation Is Associated With The Disease Activity Of Microscopic Polyangiitis

Dan Liu1,2,3, Jin-song Zhou4, Qing-ping Chen4, Chao-yang Duan1, Li Wang4, Yuan Jia3 and Ke Li1, 1Core Research Laboratory, The Second Affiliated Hospital, Xi'an Jiaotong University, Xi'an, China, 2Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi'an, China, 3Department of Rheumatology and Immunology,Clinical Immunology Center, Peking University People's Hospital, Beijing, China, 4Department of Rheumatology and Immunology, The Fifth Hospital of Xi'an, Xi’an, China

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Clinical research, complement and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis I

Session Type: Abstract Submissions (ACR)

Background/Purpose: Microscopic polyangiitis (MPA) is the most common anti-neutrophil cytoplasmic antibodies(ANCA) associated small-vessel vasculitis with specificity of the ANCA to myeloperoxidase(MPO) of neutrophils. MPA mainly affects kidneys and lungs. The kidneys are the most commonly affected organ; and kidney vasculitis can result in renal failure. The interplay of ANCA, neutrophil and complement activation has been implicated in the pathogenesis of MPA. In this study, we tried to establish the relationship of complement activation and the disease activity of MPA and to identify potential biomarkers for this disease.

Methods: Blood samples were collected from 45 MPO-ANCA positive patients who had clinical diagnosis of MPA in People’s Hospital, Peking University, after informed consent. The samples, according to serum C3 levels, were divided into two groups: normal C3 group: ≥0.8 g/L (n=18) and low C3 group: C3<0.8 g/L (n=27). Inflammatory markers (i.e. ESR, CRP), renal functional markers (i.e. BUN, creatinine, 24-hour urinary protein level), and lung diseases were evaluated in the two groups. Birmingham Vasculitis Activity Score-version 3 (BVAS[V3]) was calculated. Data was analyzed using corresponding t test, chi-square test, linear correlation analysis and binary logistic regression, respectively.

Results: We found that: 1) Compared with normal C3 group, low C3 group had significantly lowered C4 (0.17±0.08 g/L vs 0.25±0.08 g/L) but significantly increased CRP (101±57 mg/L vs 33±33 mg/L), 24-hour urinary protein (1.4±1.3g/d vs 0.6±0.5g/d), BUN (17.08±9.02 mmol/L vs 8.62±5.28 mmol/L) and BVAS(V3) (21.4±3.6 vs 15.4±3.8). 2) BVAS(V3) has a significant linear correlation with serum complement C3 level (R2=0.43, P<0.01). 3) Morbidity of severe lung injury (i.e. interstitial lung disease, pneumorrhagia) in low C3 group was higher than that in normal C3 group (92.6% vs 33.3%, X2=17.69, P<0.01).  4) C3, CRP and ESR levels were closely related to the occurrence of severe lung injury, and the logistic regression equation was: P(y)=1/(1+e-2.1+7.54×C3-0.054×CRP-0.027×ESR), in which the overall correct percentage was 93.3%.

Conclusion: Serum complement C3 levels were associated with the disease activity and clinical manifestations of MPA. Therefore, serum C3 level may represent as a biomarker for disease activity and an indicator for organ injury of MPA.


Disclosure:

D. Liu,
None;

J. S. Zhou,
None;

Q. P. Chen,
None;

C. Y. Duan,
None;

L. Wang,
None;

Y. Jia,
None;

K. Li,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/c3-activation-is-associated-with-the-disease-activity-of-microscopic-polyangiitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology